Vnitr Lek 2011, 57(10):871-875

MR-documented remission of pituitary stalk infiltration in patients with Langerhans cell histiocytosis following treatment with 2-chlorodeoxyadenosine

J. Vaníček1, Z. Adam2,*, K. Balšíková3, M. Krejčí2, L. Pour2, P. Szturz2, L. Zahradová2, R. Hájek2, R. Koukalová4, Z. Řehák4, Z. Král2, J. Mayer2
1 Klinika zobrazovacích metod Lékařské fakulty MU a FN u sv. Anny v Brně, zastupující přednosta as. MUDr. Jiří Vaníček, Ph.D.
2 Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc.
3 II. interní klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Miroslav Souček, CSc.
4 Oddělení PET CT Masarykova onkologického ústavu v Brně, přednosta prim. MUDr. Karol Bolčák, Ph.D.

In adult patients, Langerhans cell histiocytosis (LCH) manifests most frequently with one or more osteolytic lesions or, alternatively, with pulmonary involvement with nodules and cysts or with skin lesions. Infiltration of the central nervous system is a rather rare sign of LCH. The LCH cells have an unexplained affinity to hypothalamus and to pituitary stalk and, consequently, central diabetes insipidus is the most frequent clinical sign of brain involvement in LCH. We describe treatment of 2 adult patients with LCH in whom central diabetes insipidus was the first sign of LCH and MR confirmed pituitary stalk infiltration. The

first man was diagnosed with diabetes insipidus and pituitary stalk infiltration at 33 years of age. LCH was confirmed 2 years later by histology of verrucous lesions on the skin of perianal area. The disease affected the skin and CNS. The patient was treated with 2-chlorodeoxyadenosine (5 mg/m2 s.c. for 5 consecutive days of a 28-day cycle). No pituitary infiltration was evident on an MR image after the 4th cycle. Residual perianal infiltration was irradiated. The patient has been in complete remission for 44 months following treatment completion, although vasopressin and testosterone substitution is required. The

second man was also diagnosed with diabetes insipidus and pituitary stalk infiltration at 33 years of age. Pulmonary involvement was identified with high resolution CT (HRCT) and high CD1a and S-100 positive elements with bronchoalveolar lavage. This patient further had external auditory canal infiltrations causing chronic discharge from the ears. The patient was treated with 2-chlorodeoxyadenosine as above. A follow up MR after the 4th cycle showed reduction in the infiltration diameter from 5.5 to 3.0 mm. Therefore, 2-chlorodeoxyadenosine 5 mg/m2 s.c. was combined with dexamethasone 20 mg p.o. during the 5th and 6th cycle. The MR image after treatment completion showed remission of the pituitary stalk infiltrate. External auditory canal infiltration diminished as did the nodules in pulmonary parenchyma. Nevertheless, vasopressin substitution is still required. The patient has been in complete remission for 8 months from the completion of the treatment. Pituitary stalk infiltration disappeared after the treatment with 2-chlorodeoxyadenosine in 2 patients; after 4 cycles in the first and after 6 cycles (with an addition of dexamethasone during the last 2 cycles) in the second.

Keywords: Langerhans cell histiocytosis; diabetes insipidus centralis; pituitary infiltration; 2-chlorodeoxyadenosine; cladribine; otitis externa; PET-CT

Received: March 14, 2011; Accepted: April 27, 2011; Published: October 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaníček J, Adam Z, Balšíková K, Krejčí M, Pour L, Szturz P, et al.. MR-documented remission of pituitary stalk infiltration in patients with Langerhans cell histiocytosis following treatment with 2-chlorodeoxyadenosine. Vnitr Lek. 2011;57(10):871-875.
Download citation

References

  1. Ščudla V, Roček V, Dušek B et al. Multifokální eozinofilní granulom v dospělosti. Vnitř Lék 1987; 33: 1078-1086. Go to PubMed...
  2. Dufka A, Šálek T. Recidivující synkopa jako vedoucí symptom u parciálního centrálního diabetu insipidu. Interní med pro praxi 2007; 4: 195-197.
  3. Votava F. Diferenciální diagnostika polyurie a polydipsie. Čes Slov Pediat 2001; 56: 655-659.
  4. Loh JA, Verbalis JG. Disorders of water and salt metabolism associated with pituitary disease. Endocrinol Metab Clin North Am 2008; 37: 213-234. Go to original source... Go to PubMed...
  5. Müssig K, Beschorner R. Rare differential diagnosis of diabetes insipidus. Dtsch Med Wochenschr 2008; 133: 2159-2160. Go to original source... Go to PubMed...
  6. Aricò M, Girschikofsky M, Généreau T et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39: 2341-2348. Go to original source... Go to PubMed...
  7. Fichter J, Doberauer C, Seegenschmiedt H. Langerhans cell histiocytosis in adults: An interdisciplinary challenge. Dtsch Arztebl 2007; 104: 2347-2353.
  8. Allen CE, McClain KL. Langerhans cell histiocytosis: a review of past, current and future therapies. Drugs Today 2007; 43: 627-643. Go to original source... Go to PubMed...
  9. Carrera CJ, Terai C, Lotz M et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosupressive therapy. J Clin Invest 1996; 86: 1480-1488. Go to original source... Go to PubMed...
  10. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997; 32: 120-131. Go to original source... Go to PubMed...
  11. Bryson MH, Sorkin EM. Cladribine: A review of its pharmacodynamics and pharmacokinetics properties and therapeutic potential in haematologic malignancies. Drugs 1993; 46: 872-891. Go to original source... Go to PubMed...
  12. Liliemark J, Albertoni F, Hasan M et al. On the bioavailability of oral and subcutaneous 2-chlorodeoxadenosine in human. Alternative routes of administration. J Clin Oncol 1992; 10: 1514-1518. Go to original source... Go to PubMed...
  13. Robak T, Lech-Maranda E, Korycka A et al. Purine nukleoside analogs as immunosupressive and antineoplastic agents: Mechanismus of action and clinical activity. Curr Med Chem 2006; 13: 3165-3189. Go to original source... Go to PubMed...
  14. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother 2005; 6: 2435-2441. Go to original source... Go to PubMed...
  15. Saven A, Figueroa ML, Piro LD et al. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med 1993; 329: 734-735. Go to original source... Go to PubMed...
  16. Weitzman S, Wayne AS, Arceci R et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 1999; 33: 476-481. Go to original source... Go to PubMed...
  17. Imamura T, Sato T, Shiota Y et al. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol 2010; 91: 646-651. Go to original source... Go to PubMed...
  18. Weitzman S, Braier J, Donadieu J et al. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009; 53: 1271-1276. Go to original source... Go to PubMed...
  19. Pardanani A, Phyliky RL, Li CY et al. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003; 78: 301-306. Go to original source... Go to PubMed...
  20. Watts J, Files B. Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. Pediatr Hematol Oncol 2001; 18: 199-204. Go to original source... Go to PubMed...
  21. Dhall G, Finlay JL, Dunkel IJ et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 2008; 50: 72-79. Go to original source... Go to PubMed...
  22. Stine KC, Saylors RL, Saccente S et al. Eff icacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43: 81-84. Go to original source... Go to PubMed...
  23. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003; 25: 575-577. Go to original source... Go to PubMed...
  24. Mottl H, Ganevová M, Radvanská J et al. Treatment results of Langerhans cell histiocytosis with LSH II protocol. Čas Lék Čes 2005; 144: 753-755.
  25. Mottl H, Starý J, Chánová M et al. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leuk Lymphoma 2006; 47: 1881-1884. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.